(19) TZZ_Z _T (11) EP 1 778 702 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07F 9/141 (2006.01) C07D 207/08 (2006.01) 13.07.2011 Bulletin 2011/28 A61K 31/662 (2006.01) A61P 31/12 (2006.01) (21) Application number: 05791144.8 (86) International application number: PCT/US2005/025503 (22) Date of filing: 18.07.2005 (87) International publication number: WO 2006/020276 (23.02.2006 Gazette 2006/08) (54) ANTIVIRAL COMPOUNDS ANTIVIRALE VERBINDUNGEN COMPOSES ANTIVIRAUX (84) Designated Contracting States: (74) Representative: Reitstötter - Kinzebach AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Patentanwälte HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI Sternwartstrasse 4 SK TR 81679 München (DE) Designated Extension States: AL BA HR MK YU (56) References cited: EP-A- 1 337 550 WO-A-00/09543 (30) Priority: 16.07.2004 US 588633 P WO-A-00/59929 WO-A-98/17679 27.07.2004 US 591635 P WO-A-99/07733 WO-A-02/060926 WO-A-03/053349 WO-A-03/064416 (43) Date of publication of application: WO-A-03/064455 WO-A-03/064456 02.05.2007 Bulletin 2007/18 WO-A-03/066103 WO-A-03/099274 WO-A-03/099316 US-A1- 2003 186 895 (60) Divisional application: US-A1- 2003 224 977 US-A1- 2004 048 802 10178084.9 / 2 316 839 US-B1- 6 608 027 (73) Proprietor: GILEAD SCIENCES, INC. • ORVIETO F ET AL: "Novel, potent Foster City phenethylamide inhibitors of the hepatitis C virus CA 94404 (US) (HCV) NS3 protease: Probing the role of P2 aryloxyprolines with hybrid structures" (72) Inventors: BIOORGANIC & MEDICINAL CHEMISTRY • CHAUDHARY, Kleem LETTERS, OXFORD, GB, vol. 13, no. 16, 18 Hayward, CA 94544 (US) August 2003 (2003-08-18), pages 2745-2748, • FLEURY, Melissa XP002314396 ISSN: 0960-894X San Mateo, CA 94404 (US) • NI Z-J ET AL: "PROGRESS AND DEVELOPMENT • KIM, Choung, U. OF SMALL MOLECULE HCV ANTIVIRALS" San Carlos, CA 94070 (US) CURRENT OPINION IN DRUG DISCOVERY AND • MCMURTRIE, Darren, J. DEVELOPMENT, CURRENT DRUGS, LONDON, San Mateo, CA 94401 (US) GB, vol. 7, no. 4, July 2004 (2004-07), pages • SHENG, Xiaoning C. 446-459, XP009037092 ISSN: 1367-6733 Foster City, CA 94404 (US) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 1 778 702 B1 Printed by Jouve, 75001 PARIS (FR) EP 1 778 702 B1 Description FIELD OF THE INVENTION 5 [0001] The invention relates generally to compounds with HCV inhibitory activity. BACKGROUND OF THE INVENTION [0002] Improving the delivery of drugs and other agents to target cells and tissues has been the focus of considerable 10 research for many years. Though many attempts have been made to develop effective methods for importing biologically active molecules into cells, both in vivo and in vitro, none has proved to be entirely satisfactory. Optimizing the association of the inhibitory drug with its intracellular target, while minimizing intercellular redistribution of the drug, e.g., to neighboring cells, is often difficult or inefficient. [0003] Most agents currently administered to a patient parenterally are not targeted, resulting in systemic delivery of 15 the agent to cells and tissues of the body where it is unnecessary, and often undesirable. This may result in adverse drug side effects, and often limits the dose of a drug (e.g., glucocorticoids and other anti-inflammatory drugs) that can be administered. By comparison, although oral administration of drugs is generally recognized as a convenient and economical method of administration, oral administration can result in either (a) uptake of the drug through the cellular and tissue barriers, e.g., blood/brain, epithelial, cell membrane, resulting in undesirable systemic distribution, or (b) 20 temporary residence of the drug within the gastrointestinal tract. Accordingly, a major goal has been to develop methods for specifically targeting agents to cells and tissues. Benefits of such treatment includes avoiding the general physiological effects of inappropriate delivery of such agents to other cells and tissues, such as uninfected cells. [0004] Hepatitis C is recognized as a chronic viral disease of the liver which is characterized by liver disease. Although drugs targeting the liver are in wide use and have shown effectiveness, toxicity and other side effects have limited their 25 usefulness. [0005] Assay methods capable of determining the presence, absence or amounts of HCV are of practical utility in the search for inhibitors as well as for diagnosing the presence of HCV. [0006] Inhibitors of HCV are useful to limit the establishment and progression of infection by HCV as well as in diagnostic assays for HCV. 30 [0007] There is a need for HCV therapeutic agents, i.e. drugs, having improved inhibitory and pharmacokinetic prop- erties, including enhanced activity against development of viral resistance, improved oral bioavailability, greater potency and extended effective half-life in vivo. New HCV inhibitors should have fewer side effects, less complicated dosing schedules, and be orally active. In particular, there is a need for a less onerous dosage regimen, such as one pill, once per day. 35 Inhibitors of the HCV NS3 protease have been described in WO 02/060926, WO 03/064416, WO 03/064455, WO 98/17679, WO 03/064456, WO 03/066103, WO 03/ 099316, WO 03/ 053349, WO 00/ 59929, WO 02/ 060926, US 2004/ 048802, US 2003/186895, US 2003/224977, US 6,608,027, WO 03/099274, WO 00/09543 and WO 99/07733. Bioorganic & Medicinal Chemistry Letters (2003) 13: 2745-2748 discloses fenetylamid dipeptide inhibitors of the HCV NS3 protease. 40 SUMMARY OF THE INVENTION [0008] Intracellular targeting may be achieved by methods and compositions that allow accumulation or retention of biologically active agents inside cells. The present invention provides compositions and methods for inhibition of HCV or therapeutic activity against HCV. 45 [0009] The present invention relates generally to the accumulation or retention of therapeutic compounds inside cells. The invention is more particularly related to attaining high concentrations of phosphonate molecules in liver cells. Such effective targeting may be applicable to a variety of therapeutic formulations and procedures. [0010] Compositions of the invention include anti-viral compounds having usually at least one phosphonate group. Accordingly, in one embodiment, the invention provides a compound of the invention which is linked to one or more 50 phosphonate groups. [0011] In another embodiment, the invention provides a conjugate, or a pharmaceutically acceptable salt or solvate thereof. [0012] The present invention provides a compound of formula I: 55 2 EP 1 778 702 B1 5 10 15 or a pharmaceutically acceptable salt, enantiomer or solvate thereof, wherein: R1 is independently selected from H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, halogen, haloalkyl, alkylsulfon- 20 amido, arylsulfonamido,-C(O)NHS(O)2-, or -S(O)2-, optionally substituted with one or more A3; R2 is -C(Y1)(A3), R3 is H or (C1-6)alkyl; Y1 is independently O, S, N(A3); Z is O; 25 1 1 3 Z is -Y -A ; Z2a is H, (C1-10)alkyl (C2-10)alkenyl, or (C2-10)alkynyl, or Z2a optionally forms a cycle with Q1; Z2b is H, (C1-6)alkyl, (C2-8)alkenyl, or (C2-8)alkynyl; Q1 is (C1-8)alkyl, (C2-8)alkenyl, or (C2-8)alkynyl; 3 A is independently selected from -OH, -C(O)OH, alkyl, alkenyl, alkynyl, amino, amido, imido, imino, halogen, CF3, 30 2 2 2 2 CH2CF3, cycloalkyl, nitro, aryl, aralkyl, alkoxy, aryloxy, heterocycle, heteroaryl, -C(A )3,-C(A )2-C(O)A C(O)A , -C(O) 2 2 2 2 OA ,-O(A), -N(A )2,-S(A), -(CH2)m-heterocycle, -(CH2)mC(O)Oalkyl, -O-(CH2)m-O-C(O)-Oalkyl, -O-(CH2)m-O-C (O)-(CH2)m-alkyl, -(CH2)mO-C(O)-O-alkyl, -(CH2)mO-C(O)-O-cycloalkyl, -N(H)C(Me)C(O)O-alkyl, or alkoxy arylsulfon- amide, wherein each A3 maybe optionally substituted with 1 to 4 35 -R1, halogen, alkyl, alkenyl, alkynyl, aryl, carbocycle, heterocycle, aralkyl, aryl sulfonamide, aryl alkylsulfonamide, aryloxy sulfonamide, aryloxy alkylsulfonamide, aryloxy arylsulfonamide, alkyl sulfonamide, alkyloxy sulfonamide, alkyloxy alkyl- sulfonamide, -(CH2)mheterocycle, -(CH2)m-C(O)O-alkyl, -O(CH2)mOC(O)Oalkyl, -O-(CH2)m-O-C(O)-(CH2)m-alkyl, - (CH2)m-O-C(O)-O-alkyl, -(CH2)m-O-C(O)-Ocycloalkyl, -N(H)C(CH3)C(O)O-alkyl, or alkoxy arylsulfonamide, optionally substituted with R1; 40 A2 is independently selected from H, alkyl, alkenyl, alkynyl, amino, amino acid, alkoxy, aryloxy, cyano, haloalkyl, cy- cloalkyl, aryl, heteroaryl, alkylsulfonamide, or arylsulfonamide; and m is 0 to 6, wherein, if not indicated otherwise, alkyl is (C1-18)alkyl; alkenyl is (C2-18)alkenyl; alkynyl is (C2-18)alkynyl; cycloalkyl is (C3-7)cycloalkyl; aryl is (C6-20)aryl; aralkyl is (C6-20)aralkyl; alkoxy is (C1-18)alkoxy; carbocycle is a saturated, 45 unsaturated or aromatic (C3-7)monocycle, (C7-12)bicycle or a polycycle with up to 20 carbon atoms; heterocycle is a carbocycle as defined before, wherein 1, 2, 3, or 4 carbon atoms have been replaced with O, N or S. [0013] The present invention provides a compound of formula XI, 50 55 3 EP 1 778 702 B1 5 10 15 20 or a pharmaceutically acceptable salt, enantiomer solvate or prodrug thereof, wherein R1,R2,R3,Z,Z1,Z2b,m,A3, and A2 are as defined above and Z2a forms a cycle with Q1.